Lilly moves toward psoriasis showdown with Novartis in EU

Look out, Novartis ($NVS). Eli Lilly ($LLY) is now one step closer in the EU to challenging the Swiss pharma's new psoriasis standout, Cosentyx, with its own next-gen therapy, ixekizumab. The European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) has backed a go-ahead for the therapy, and regulators typically green-light recommended approvals within three months. More from FierceBiotech

Suggested Articles

Despite a veritable graveyard of drug prospects in hard-to-treat glioblastoma, Bayer hopes underperforming Stivarga can crack the code in new trials.

Online pharmacy Valisure has criticized the FDA for what it deems as irrational standards in the levels of suspected carcinogens in the drug supply.

GSK is grouping some non-core consumer products into three portfolios for sell-offs so it can win EU antitrust clearance for its Pfizer deal.